Archived

Content that has been automatically archived

These medications can reduce opioid deaths. Why aren’t they being used more?

This post has been archived and contains information that may be out of date.

Walter Ginter began using heroin in the early 1970s while serving in the Army. By 1977, desperate to kick the habit, he turned to daily doses of methadone, a synthetic opioid that eases withdrawal and decreases cravings. The treatment worked.

“I have a good life today,” says Ginter, 69, project director for the New York-based Medication Assisted Recovery Support Project.  “I wouldn’t have it without medication.”

Ginter was a member of a National Academies of Sciences, Engineering and Medicine committee that examined the three medications — methadone, buprenorphine (typically sold under the Suboxone brand name) and extended-release naltrexone (Vivitrol) — that the government has approved to treat opioid addiction.

Celebrate National Volunteer Week April 7-12

This post has been archived and contains information that may be out of date.

Established in 1974, National Volunteer Week is an opportunity to recognize and thank volunteers who lend their time, talent, voice, and support to causes they care about in their hospital and community. Their stories can serve to inspire others to find ways to take action that creates change.

Points of Light is the world’s largest organization dedicated to volunteer service, helping millions of volunteers change the world. During National Volunteer Week, CHA encourages hospitals to celebrate the impact your volunteers have made in your hospital and community. 

Lobby Action Day

This post has been archived and contains information that may be out of date.

This post has been archived and contains information that may be out of date.

CDPH Issues Health Advisory About Measles Cases

This post has been archived and contains information that may be out of date.

A new health advisory from the California Department of Public Health (CDPH) reminds providers to be aware of potential measles cases, as 16 cases have been reported in California since Jan. 1. CDPH notes that providers should not rule out a measles diagnosis based solely on patients reporting they previously received a measles immunization.

CHA DataSuite Releases Fourth Quarter 2018 Impact Analyses

This post has been archived and contains information that may be out of date.

CHA DataSuite has issued hospital-specific analyses showing the estimated impact of the federal fiscal year (FFY) 2020 Medicare inpatient Hospital-Acquired Condition (HAC) Reduction Program as well as the hospital Value-Based Purchasing (VBP) Program, based on publicly available data and program rules established by the Centers for Medicare & Medicaid Services (CMS). 

Hospital Leaders Advance Debate on Seismic Mandate

This post has been archived and contains information that may be out of date.

CHA member hospitals today gathered in Sacramento for a Lobby Action Day (photo gallery) to urge legislators to support Senate Bill 758 (Portantino, D-La Canada Flintridge), a bill that will be amended to give hospitals the flexibility they need to tailor post-disaster care to meet the unique needs of their communities. Today’s event followed a radio interview that CHA President & CEO Carmela Coyle participated in yesterday about a new report that says current seismic requirements may be outdated and prohibitively expensive.

New Website Allows Providers to Check Maximum 340B Drug Prices

This post has been archived and contains information that may be out of date.

A new website allows 340B Drug Pricing Program participants to determine the maximum drug companies can charge them for medications sold under the program. The website comes as a result of a recent lawsuit filed against the Health Resources and Services Administration by the American Hospital Association, which sought to force implementation of a final rule impacting drug ceiling prices and civil monetary penalties for manufacturers.

Investment State-of-Play in Big Pharma: Bayer’s Eugene Borukhovich Weighs In

This post has been archived and contains information that may be out of date.

Bayer’s G4A team launched their 2019 program today, so here’s a little help for anyone curious about the state of pharma startup investment and what it takes to land a deal there these days.

I had the chance to pick the brain of Bayer’s Global Head of Digital Health, Eugene Borukhovich, during JP Morgan Healthcare Week and pulled out these three gloriously thought-provoking soundbites from our conversation to give you some insight as to the mindset over at big Bayer.